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BACKGROUND
Darolutamide is a structurally unique androgen-receptor antagonist that is under de-
velopment for the treatment of prostate cancer. We evaluated the efficacy of darolu-
tamide for delaying metastasis and death in men with nonmetastatic, castration-
resistant prostate cancer.
METHODS
We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving 
men with nonmetastatic, castration-resistant prostate cancer and a prostate-specific 
antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 
ratio to receive darolutamide (600 mg [two 300-mg tablets] twice daily) or placebo 
while continuing androgen-deprivation therapy. The primary end point was metas-
tasis-free survival, with the presence of metastasis determined by independent cen-
tral review of radiographic imaging every 16 weeks.
RESULTS
In total, 1509 patients underwent randomization (955 to the darolutamide group and 
554 to the placebo group). In the planned primary analysis, which was performed 
after 437 primary end-point events had occurred, the median metastasis-free survival 
was 40.4 months with darolutamide, as compared with 18.4 months with placebo 
(hazard ratio for metastasis or death in the darolutamide group, 0.41; 95% confidence 
interval, 0.34 to 0.50; P<0.001). Darolutamide was also associated with benefits with 
regard to all secondary end points, including overall survival, time to pain progres-
sion, time to cytotoxic chemotherapy, and time to a symptomatic skeletal event. The 
incidence of adverse events that occurred or worsened during the treatment period 
and had a frequency of 5% or more or were of grade 3 or higher was similar in the 
two groups; all such events except fatigue occurred in less than 10% of patients in 
either group. The percentage of patients who discontinued the assigned regimen 
because of adverse events was 8.9% in the darolutamide group and 8.7% in the 
placebo group. Darolutamide was not associated with a higher incidence of seizures, 
falls, fractures, cognitive disorder, or hypertension than placebo.
CONCLUSIONS
Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free 
survival was significantly longer with darolutamide than with placebo. The incidence 
of adverse events was similar for darolutamide and placebo. (Funded by Bayer 
HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614.)
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Androgen-deprivation therapy is part of the standard of care for patients whose prostate cancer recurs after pri-
mary treatment.1-4 However, despite receiving an-
drogen-deprivation therapy, most of these pa-
tients will have disease progression, initially 
manifesting as rising levels of prostate-specific 
antigen (PSA).5 Some of these patients have an 
absence of metastases on conventional imaging 
and are classified as having nonmetastatic, 
castration-resistant prostate cancer.6 Delaying 
the development of metastases in these patients 
is a key therapeutic goal, since metastasis in 
bone, soft tissue, or viscera is associated with 
both morbidity and prostate cancer–specific mor-
tality.7-9
The androgen-receptor inhibitors apalu-
tamide and enzalutamide have recently been 
approved for the treatment of nonmetastatic, 
castration-resistant prostate cancer on the basis 
of phase 3 trials showing significantly longer 
metastasis-free survival with these agents than 
with placebo.10,11 Data on overall survival or pain 
associated with these agents are still immature. 
However, patients with nonmetastatic, castra-
tion-resistant prostate cancer, who may have 
adverse effects from their ongoing androgen-
deprivation therapy, may have additional associ-
ated adverse events and toxic effects from these 
agents. Thus, there is a need for therapies with 
improved safety and toxicity profiles.
Darolutamide is an androgen-receptor antag-
onist with a distinct structure that offers a po-
tential for fewer and less severe toxic effects 
than apalutamide and enzalutamide because of 
its low penetration of the blood–brain barrier12-14 
and low binding affinity for γ-aminobutyric acid 
type A receptors, as shown in preclinical stud-
ies.15 After observing the significant antitumor 
activity and good side-effect profile shown in 
phase 1 and 2 studies involving men with meta-
static, castration-resistant prostate cancer,16-19 we 
conducted the multinational, randomized, dou-
ble-blind, placebo-controlled, phase 3 Androgen 
Receptor Antagonizing Agent for Metastasis-free 
Survival (ARAMIS) trial to evaluate the efficacy 
and safety of darolutamide in men with non-
metastatic, castration-resistant prostate cancer. 
The primary end point was metastasis-free sur-
vival, an established end point in trials involving 
castration-resistant prostate cancer.
Me thods
Trial Design and Conduct
The trial was sponsored by Orion Pharma and 
Bayer HealthCare; both sponsors developed the 
trial design with the first and last authors. The 
trial was conducted in 36 countries worldwide in 
409 centers. The institutional review board at 
each participating institution approved the trial, 
which was conducted in compliance with the 
principles of the Declaration of Helsinki and in 
accordance with the International Conference on 
Harmonisation guidelines for Good Clinical Prac-
tice. All patients provided written informed con-
sent. An independent data and safety monitoring 
board reviewed unblinded safety data through-
out the trial. The data were collected by the in-
vestigators, analyzed by statisticians who were 
employed by the sponsors, and interpreted by the 
authors, including employees of the sponsors. 
Bayer HealthCare provided funding for medical 
writing and editing assistance. The authors re-
viewed and approved the manuscript that was 
submitted for publication. The authors assume 
responsibility for the completeness and accuracy 
of the data and for the fidelity of the trial and 
this report to the protocol and statistical analysis 
plan, available with the full text of this article at 
NEJM.org.
Patients
Patients were eligible for participation if they 
were 18 years of age or older and had histologi-
cally or cytologically confirmed adenocarcinoma 
of the prostate. Patients were required to have 
castration-resistant prostate cancer, a baseline PSA 
level of at least 2 ng per milliliter, a PSA doubling 
time of 10 months or less, and an Eastern Coop-
erative Oncology Group (ECOG) performance sta-
tus of 0 or 1 (scores range from 0 to 5, with 
higher numbers reflecting greater disability). At 
screening, all patients underwent a radionuclide 
bone scan of the whole body and computed to-
mography (CT) or magnetic resonance imaging 
(MRI) of the pelvis, abdomen, and chest; patients 
with detectable metastases or a history of meta-
static disease were excluded, although the pres-
ence of pelvic lymph nodes less than 2 cm in 
diameter in the short axis below the aortic bifur-
cation was allowed. Previous seizure or condi-
tions predisposing to seizure were not exclusion-
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ary. Full details of the criteria for patient selection 
are provided in the Supplementary Appendix, 
available at NEJM.org.
Trial Design and Regimens
At trial initiation, patients were randomly assigned 
in a 2:1 ratio in a double-blind manner to receive 
either darolutamide (600 mg given as two 300-mg 
tablets) twice daily with food (a daily dose of 
1200 mg) or matched placebo. Randomization 
was stratified according to PSA doubling time 
(≤6 months or >6 months) and the use of osteo-
clast-targeted therapy at randomization (yes or no). 
Patients continued taking the randomly assigned 
regimen until protocol-defined progression, dis-
continuation of the regimen because of adverse 
events, or withdrawal of consent. Patients contin-
ued to receive androgen-deprivation therapy (lu-
teinizing hormone–releasing hormone agonist or 
antagonist) throughout the trial. Patients who 
initiated a prohibited therapy (listed in the pro-
tocol) before confirmation of metastasis had to 
discontinue the trial regimen and were followed 
for survival status.
Assessments
Information on the patients’ demographic char-
acteristics, relevant medical history, and pertinent 
clinical conditions was obtained at screening. 
Data on vital signs and laboratory safety assess-
ments were obtained at the trial research center 
at screening and at every scheduled visit (at days 
1, 15, and 29; at 16 weeks; and at 16-week inter-
vals thereafter). Serum PSA level and pain (evalu-
ated with the use of the Brief Pain Inventory 
Short-Form [BPI-SF] questionnaire, a 10-point scale 
on which higher numbers reflect greater pain; 
minimum clinically important difference, 2 points) 
were assessed at screening, day 1, week 16, and 
every subsequent visit until the end of the trial 
or death. Health-related quality-of-life instruments 
were assessed at screening, day 1, week 16, and 
the end of the treatment period with the Func-
tional Assessment of Cancer Therapy–Prostate 
(FACT-P; the total score is the sum of the scores 
of 39 items of the questionnaire and ranges 
from 1 to 156, with higher scores indicating bet-
ter quality of life; minimum clinically important 
difference, 10 points), the prostate cancer–specific 
subscale of the FACT-P (FACT-P PCS; minimum 
clinically important difference, 3 points),20 and 
the generic EuroQol Group 5-dimension 3-level 
(EQ-5D-3L; five dimensions, each with three lev-
els of response, are summarized as an index score 
ranging from −0.59 to 1, with higher scores in-
dicating better health states; minimum clinically 
important difference, 0.06 points); the FACT-P 
PCS was also given every 16 weeks until the end 
of the trial or death. The European Organisation 
for Research and Treatment of Cancer quality of 
life questionnaire urinary symptoms subscale 
(EORTC-QLQ-PR25, a 25-item questionnaire on 
which higher scores indicate a greater effect of 
symptoms on quality of life; minimum clinically 
important difference, 8 points)21 was given at 
screening, day 1, week 16, and every 16 weeks 
until the end of the treatment period. Disease 
assessments — including evaluation of ECOG 
performance status, bone scans, and CT and MRI 
of the chest, abdomen, and pelvis — were per-
formed at screening, week 16, and every subse-
quent 16-week visit. All scans were evaluated both 
locally and by blinded independent central review.
Data on adverse events that occurred or wors-
ened during the treatment period, including the 
type, severity (according to the National Cancer 
Institute Common Terminology Criteria for Ad-
verse Events, version 4.03),22 and seriousness of 
the events and whether they were assessed by the 
investigator as being related to the trial regimen, 
were recorded at each visit. Safety was evaluated 
in all patients who underwent randomization 
and received at least one dose of darolutamide or 
placebo.
End Points
The primary end point was metastasis-free sur-
vival, defined as the time from randomization to 
confirmed evidence of distant metastasis on im-
aging or death from any cause, whichever occurred 
first. The blinded central imaging review for ef-
ficacy was performed by a pool of radiologists 
separate from those who performed the blinded 
central imaging review for eligibility. During the 
central efficacy imaging review, which included 
the baseline scans, some patients were retrospec-
tively classified as having metastases at baseline. 
These patients were included in the primary analy-
sis of metastasis-free survival. Sensitivity analyses 
are summarized in the Supplementary Appendix.
The secondary end points were overall sur-
vival, time to pain progression (defined as either 
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an increase of ≥2 points from baseline in the 
score assessed with the BPI-SF questionnaire or 
initiation of opioid treatment for cancer pain, 
whichever occurred first), time to first symptom-
atic skeletal event (defined as external-beam radia-
tion therapy to relieve skeletal symptoms, new 
symptomatic pathologic bone fracture, occur-
rence of spinal cord compression, or tumor-related 
orthopedic surgical intervention), and time to first 
cytotoxic chemotherapy.
Exploratory end points included progression-
free survival (defined as the time from random-
ization to evidence of any radiographic disease 
progression, including local relapse or new patho-
logic lymph nodes, or death from any cause, 
whichever occurred first), time to first prostate 
cancer–related invasive procedure, time to initia-
tion of subsequent antineoplastic therapy, PSA 
progression and response, deterioration in ECOG 
performance status, and quality of life. The time 
to PSA progression from randomization was de-
fined in accordance with Prostate Cancer Work-
ing Group 2 (PCWG2) criteria (Table S1 in the 
Supplementary Appendix).23 PSA response was 
defined as a decline of at least 50% from baseline 
in the PSA level, according to PCWG2 criteria.23 
Deterioration in ECOG performance status was 
defined as an increase to a score of 3 or higher.
Statistical Analysis
The sample size was calculated on the basis of the 
primary end point, metastasis-free survival. As-
suming a hazard ratio of 0.71 for death or metas-
tasis in the darolutamide group, we calculated 
that a sample of 1500 patients (randomly assigned 
in a 2:1 ratio to receive darolutamide or placebo) 
with approximately 385 primary end-point events 
would provide the trial with 91% power to detect 
a significant difference in metastasis-free survival 
with the use of a log-rank test at a two-sided sig-
nificance level of 0.05.
The full intention-to-treat population, which 
was made up of all patients who underwent ran-
domization, was included in the analysis of the 
primary end point; patients with metastases at 
baseline were counted as having an event at ran-
domization. Subgroup analyses of metastasis-free 
survival and overall survival were performed to 
determine the effect of demographic or baseline 
characteristics. Randomization stratification fac-
tors were used to adjust analyses of the primary 
and all secondary efficacy end points. Data from 
patients without events were censored at the last 
assessment date. Kaplan–Meier curves, including 
median survival times and their 95% confidence 
intervals, were calculated; the hazard ratio was 
calculated with a Cox proportional-hazards model.
Secondary and exploratory end points were 
analyzed with the same methods as the primary 
end point, with the exception of the percentage 
of patients with PSA response and percentage of 
patients with deterioration in ECOG performance 
status, which were analyzed with the Cochran–
Mantel–Haenszel test. Secondary end points were 
evaluated in a hierarchical order, with a signifi-
cance level of 0.05 split between the primary 
analysis and final analysis (planned to occur after 
240 deaths from any cause) of secondary end 
points. The end point of overall survival was used 
to determine the alpha spend and significance 
threshold for each of the secondary end points. 
For quality-of-life variables, an analysis of covari-
ance model was used to compare the time-adjust-
ed area under the curve (AUC) between groups, 
with covariates for baseline scores and random-
ization stratification factors. The least-squares 
mean and 95% confidence interval was estimated 
for each group and for the difference between 
the groups.
Statistical analysis and generation of patient 
data listings were performed with the use of SAS 
for Windows, version 9.2 (SAS Institute). Incom-
plete data on event occurrence dates were imputed 
as the earliest possible date.
R esult s
Patients
Patients were enrolled between September 2014 
and March 2018. The intention-to-treat population 
included 1509 patients (955 in the darolutamide 
group and 554 in the placebo group); 1 patient in 
the darolutamide group did not start treatment 
(Fig. S1 in the Supplementary Appendix). Patient 
demographic and clinical characteristics were sim-
ilar in the two trial groups (Table 1). The data-
collection cutoff date for the primary analysis was 
September 3, 2018; the median follow-up time was 
17.9 months. At that time, the median duration of 
the treatment period was 14.8 months in the dar-
olutamide group and 11.0 months in the placebo 
group, and 64% of the patients in the darolutamide 
group and 36% in the placebo group were still re-
ceiving the assigned trial regimen.
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Primary End Point
The primary analysis of metastasis-free survival 
was performed after metastasis or death had oc-
curred in 437 patients (Table S2 in the Supple-
mentary Appendix). The median metastasis-free 
survival was 40.4 months in the darolutamide 
group, as compared with 18.4 months in the pla-
cebo group (hazard ratio for metastasis or death 
in the darolutamide group, 0.41; 95% confidence 
interval [CI], 0.34 to 0.50; P<0.001) (Fig. 1A). The 
treatment effect of darolutamide with regard to 
metastasis-free survival was consistently favor-
able across all prespecified subgroups, including 
in patients with PSA doubling times of 6 months 
or less or more than 6 months (Fig. 1B).
Secondary End Points
Darolutamide was associated with greater ben-
efits than placebo for all secondary end points 
(Table 2). At this interim analysis of overall sur-
Characteristic
Darolutamide 
(N = 955)
Placebo 
(N = 554)
Median age (range) — yr 74 (48–95) 74 (50–92)
Geographic region — no. (%)
North America 108 (11) 76 (14)
Asia-Pacific 119 (12) 67 (12)
Rest of the world† 728 (76) 411 (74)
Median time from initial diagnosis (range) — mo 86.2 (2.6–337.5) 84.2 (0.5–344.7)
Presence of lymph nodes on central imaging review — no. (%)
Yes 163 (17) 158 (29)
No 792 (83) 396 (71)
Median serum PSA level (range) — ng/ml 9.0 (0.3–858.3) 9.7 (1.5–885.2)
PSA doubling time
Median (range) — mo 4.4 (0.7–11.0) 4.7 (0.7–13.2)
≤6 mo — no. (%) 667 (70) 371 (67)
>6 mo — no. (%) 288 (30) 183 (33)
Median serum testosterone level (range) — nmol/liter‡ 0.6 (0.2–25.9) 0.6 (0.2–7.3)
ECOG performance status — no. (%)§
0 650 (68) 391 (71)
1 305 (32) 163 (29)
Use of bone-sparing agent — no. (%)
Yes 31 (3) 32 (6)
No 924 (97) 522 (94)
Previous hormonal therapy agents received — no. (%)¶
One 177 (19) 103 (19)
Two or more 727 (76) 420 (76)
Not applicable‖ 51 (5) 31 (6)
*  Percentages may not total 100 because of rounding. PSA denotes prostate-specific antigen.
†  This category predominantly includes European countries (15% of these patients came from non-European countries).
‡  Testosterone levels from screening or day 1 could be used for eligibility, and all patients met the inclusion criterion of 
having a testosterone level lower than 1.7 nmol per liter.
§  Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5, with higher scores reflecting
greater disability.
¶  Common previous hormonal therapies for prostate cancer (received by ≥10% of all patients) included leuprolide (52%), 
goserelin (32%), triptorelin (29%), bicalutamide (66%), flutamide (13%), and cyproterone (11%).
‖  This category includes patients who underwent surgical castration.
Table 1. Patient Demographic and Clinical Characteristics at Baseline.*
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1.0
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0.9
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0.5
0.2
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0 28 36 44 48
Months
B Subgroup Analysis of Metastasis-free Survival
A Kaplan–Meier Analysis of Metastasis-free Survival
Hazard ratio, 0.41 (95% CI, 0.34–0.50)
P<0.001
Median
Metastasis-free
Survival (95% CI) 
No. at Risk
Darolutamide
Placebo
955
554
116
29
24
189
50
37
4
32
68
12
2
0
40
18
0
4 8 12 16 20
817
368
675
275
506
180
377
117
262
75
0
0
Darolutamide
Placebo
Darolutamide
Placebo
40.4 (34.3–NR)
18.4 (15.5–22.3)
mo
0.500 1.000 3.5003.0002.5002.0001.500
Placebo BetterDarolutamide Better
Baseline PSA doubling time
>6 mo
≤6 mo
Osteoclast-targeted therapy at baseline
Yes
No
PSA level at baseline
>20 ng/ml
>10 to ≤20 ng/ml
≤10 ng/ml
PSA level at baseline relative to median
At or below median
Above median
Gleason score
≥7
<7
Age
<65 yr
65–74 yr
75–84 yr
≥85 yr
Geographic region
Rest of world
North America
Asia-Pacific
Presence of regional pathologic lymph
Yes
No
ECOG score at baseline
1
0
Race or ethnic group
White
Other
Asian
Hispanic or Latino
No. of previous hormonal therapies
Two or more
One
Overall
No. of Patients Hazard Ratio (95% CI)Subgroup
0.38 (0.26–0.55)
0.41 (0.33–0.52)
0.22 (0.08–0.57)
0.43 (0.36–0.53)
0.39 (0.29–0.54)
0.48 (0.32–0.72)
0.39 (0.29–0.53)
0.38 (0.28–0.52)
0.44 (0.34–0.56)
0.40 (0.32–0.50)
0.42 (0.28–0.63)
0.59 (0.37–0.95)
0.35 (0.26–0.47)
0.43 (0.31–0.60)
0.51 (0.27–0.96)
0.47 (0.38–0.58)
0.19 (0.10–0.35)
0.35 (0.19–0.65)
0.28 (0.15–0.51)
0.46 (0.35–0.61)
0.50 (0.36–0.69)
0.38 (0.30–0.48)
0.43 (0.35–0.53)
0.48 (0.08–3.05)
0.32 (0.18–0.59)
0.87 (0.29–2.60)
0.42 (0.34–0.53)
0.33 (0.22–0.52)
0.42 (0.35–0.50)
0.000
469
1040
64
1445
379
337
793
755
754
1106
359
197
589
593
130
1139
184
186
149
810
468
1041
1194
15
193
47
1147
280
1509
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vival after 136 deaths (78 in the darolutamide 
group and 58 in the placebo group), darolutamide 
was associated with a lower risk of death than 
placebo (hazard ratio for death, 0.71; 95% CI, 
0.50 to 0.99; P = 0.045) (Fig. 2A). The time to 
pain progression was longer in the darolutamide 
group than in the placebo group (median, 40.3 
months vs. 25.4 months; hazard ratio, 0.65; 
95% CI, 0.53 to 0.79; P<0.001) (Table 2, and Fig. 
S2A in the Supplementary Appendix). The results 
with regard to the time to first cytotoxic chemo-
therapy and time to first symptomatic skeletal 
event also favored darolutamide (Table 2). Among 
patients who discontinued the trial regimen, 29.5% 
in the darolutamide group and 36.7% in the 
placebo group received subsequent approved ther-
apy for metastatic castration-resistant prostate 
cancer. The most common subsequent treatments 
were docetaxel, abiraterone acetate, and enzalu-
tamide (Table S3 in the Supplementary Appendix); 
the frequency of use of abiraterone and enzalu-
tamide was similar across all geographic regions.
Exploratory End Points
Median progression-free survival was 36.8 months 
in the darolutamide group and 14.8 months in 
the placebo group (hazard ratio for disease pro-
gression or death, 0.38; 95% CI, 0.32 to 0.45; 
P<0.001) (Fig. S2B in the Supplementary Appen-
dix). The median time to PSA progression was 
33.2 months with darolutamide and 7.3 months 
with placebo (hazard ratio for PSA progression 
or death, 0.13; 95% CI, 0.11 to 0.16; P<0.001) 
(Fig. 2B). The results for other end points also 
favored darolutamide (Table 2).
Patient-reported quality of life was similar in 
the darolutamide group and placebo group. Dif-
ferences in least-squares mean time-adjusted AUC 
scores consistently favored darolutamide and were 
significant for BPI-SF (pain severity and pain in-
terference scores), FACT-P (Physical Well-Being, 
Emotional Well-Being, PCS, General, FACT-P total, 
and Trial Outcome Index), and the EORTC-QLQ-
PR25 urinary symptoms subscale, although the 
clinically meaningful thresholds were not reached 
(Table S4 in the Supplementary Appendix).
Safety
Overall, adverse events were reported by 83.2% of 
the patients who received darolutamide and 76.9% 
of the patients who received placebo. The major-
ity were grade 1 or 2 (54.6% with darolutamide 
and 54.2% with placebo); grade 3 or 4 adverse 
events occurred in 24.7% of patients receiving 
darolutamide and in 19.5% of those receiving 
placebo. The incidence of grade 5 adverse events 
was similar in the darolutamide group and the 
placebo group (3.9% and 3.2%, respectively) 
(Table S5 in the Supplementary Appendix); one 
death in the darolutamide group and two deaths 
in the placebo group were considered to be related 
to the trial regimen. Serious adverse events oc-
curred in 24.8% of patients in the darolutamide 
group and 20.0% in the placebo group. The per-
centage of patients who discontinued the assigned 
regimen because of adverse events was similar in 
the two groups (8.9% in the darolutamide group 
and 8.7% in the placebo group) (Table 3).
The incidence of adverse events was generally 
similar in the darolutamide and placebo groups; 
with the exception of fatigue, all adverse events 
that occurred or worsened during the treatment 
period that had a frequency of 5% or greater oc-
curred in less than 10% of the patients in either 
group (Table 3). Key adverse events that are known 
to be associated with next-generation androgen-
receptor inhibitors, such as fracture, falls, seizures, 
and weight loss, were analyzed after grouping of 
Figure 1 (facing page). Kaplan−Meier Estimates  
and Subgroup Analyses of Metastasis-free Survival  
(Intention-To-Treat Population).
Hazard ratios were based on Cox regression models. The 
analysis shown in Panel A was stratified according to 
prostate-specific antigen (PSA) doubling time (≤6 months 
or >6 months) and the use of osteoclast-targeted ther-
apy at randomization (yes or no). NR denotes not 
reached. The analyses shown in Panel B, including the 
analysis of the overall population, were conducted 
without stratification factors. Gleason scores range 
from 6 to 10, with higher scores indicating higher-risk 
cancer. The “rest of the world” geographic region was 
predominantly made up of European countries (15% 
of these patients came from non-European countries), 
and a post hoc analysis of metastasis-free survival in 
European countries (Austria, Belgium, Germany, Spain, 
Finland, France, United Kingdom, Italy, Sweden, Por-
tugal, Czech Republic, Estonia, Hungary, Lithuania, 
Poland, Romania, Russia, Serbia, Turkey, Ukraine,  
Belarus, Bulgaria, Latvia, and Slovakia) gave a hazard 
ratio very similar to that for this group. Eastern Coop-
erative Oncology Group (ECOG) performance status 
ranges from 0 to 5, with higher scores reflecting great-
er disability. The 52 patients of African descent could 
not be included in the analysis according to race or 
ethnic group because the number of events was too 
small to allow calculation of a hazard ratio.
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synonymous or pathophysiologically related ad-
verse events that occurred or worsened during 
the treatment period; most showed small or no 
differences in incidence between the darolutamide 
group and the placebo group. The incidence of 
seizures was 0.2% in both groups. Incidences of 
other adverse events of interest, including hyper-
tension, rash, dizziness, and cognitive disorder, 
differed only slightly between the darolutamide 
group and the placebo group. After adjustment 
for duration of the treatment or observation pe-
riod, the between-group differences in the inci-
dences of adverse events of interest either de-
creased or disappeared.
Discussion
Darolutamide is a nonsteroidal androgen-recep-
tor antagonist that is structurally distinct from 
other androgen-receptor inhibitors, consisting of 
two pharmacologically active diastereomers.14 In 
our trial, darolutamide prolonged metastasis-free 
survival to 40.4 months, 22 months longer than 
with placebo. The risk of metastasis or death from 
any cause was reduced by 59%, and the benefit 
was consistent across all subgroups, including 
the subgroup of patients with lower-risk disease. 
The results for the secondary end point of overall 
survival also favored darolutamide, although the 
prespecified alpha split between the primary and 
the final analysis prevented the significance crite-
ria from being met in this analysis. The results 
with regard to all secondary end points supported 
that of the primary end point, and consistent ef-
ficacy was observed for metastasis-free, overall, 
and progression-free survival.
The median metastasis-free survival with dar-
olutamide in the current trial is similar to that 
in two previous randomized, controlled trials in-
volving patients with nonmetastatic, castration-
resistant prostate cancer. The median metastasis-
free survival was 36.6 months with enzalutamide 
(vs. 14.7 months with placebo) in the PROSPER 
phase 3 trial and was 40.4 months with apalu-
tamide (vs. 16.2 months with placebo) in the 
SPARTAN (Selective Prostate Androgen Receptor 
Targeting with ARN-509) phase 3 trial.10,11 Fa-
tigue and asthenia, which are common adverse 
events in patients receiving hormone-targeted 
therapy for advanced prostate cancer, were less 
common in the current trial than in the PROSPER 
or SPARTAN trial.10,11 In contrast to apalutamide 
and enzalutamide, darolutamide was not associ-
ated with a higher incidence of falls or fractures 
End Point
Darolutamide 
(N = 955)
Placebo 
(N = 554)
Hazard Ratio 
 (95% CI) P Value
Median 
 Duration
No. of 
 Events
Median 
 Duration
No. of 
 Events
mo mo
Secondary end points
Overall survival NR 78 NR 58 0.71 (0.50–0.99) 0.045
Time to pain progression 40.3 251 25.4 178 0.65 (0.53–0.79) <0.001
Time to cytotoxic chemotherapy NR 73 38.2 79 0.43 (0.31–0.60) <0.001
Time to first symptomatic skeletal event NR 16 NR 18 0.43 (0.22–0.84) 0.01
Time-to-event exploratory end points
Progression-free survival 36.8 255 14.8 258 0.38 (0.32–0.45) <0.001
Time to PSA progression 33.2 226 7.3 368 0.13 (0.11–0.16) <0.001
Time to first prostate cancer–related  
invasive procedure
NR 34 NR 44 0.39 (0.25–0.61) <0.001
Time to initiation of subsequent anti-
neoplastic therapy
NR 48 NR 70 0.33 (0.23–0.47) <0.001
*  A total of 798 patients (84%) in the darolutamide group and 45 (8%) in the placebo group had a PSA response of 50% or greater. NR de-
notes not reached.
Table 2. Prespecified Secondary and Exploratory Efficacy End Points (Intention-To-Treat Population).*
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than placebo,10,11 despite few patients using osteo-
clast-targeted therapies. Seizures were noted as a 
potential risk in the dose-escalation and toxicity 
studies of enzalutamide,24 whereas the preclini-
cal and clinical data for darolutamide did not 
indicate any proconvulsive potential.19 Patients 
with a history of seizure were therefore allowed 
to enter the trial, in contrast to the SPARTAN and 
PROSPER trials. The incidence of seizure events 
was low and similar in the darolutamide and 
placebo groups (Table 3); none of the patients 
with a medical history of seizure (12 in the dar-
olutamide group) had a seizure during the trial. 
The incidences of rash and hypothyroidism, which 
were higher among patients receiving apalutamide 
than among those receiving placebo,10 were low 
and similar in the darolutamide and placebo 
groups, as were the incidences of hypertension 
and central nervous system (CNS)–related adverse 
events. In the PROSPER and SPARTAN trials, hy-
pertension and CNS-related adverse effects, such 
as mental-impairment disorders and dizziness, 
were more common among patients receiving 
enzalutamide or apalutamide than among those 
Figure 2. Kaplan−Meier Estimates of Overall Survival and Time to PSA Progression.
Hazard ratios were based on Cox regression models that were stratified according to PSA doubling time (≤6 months 
or >6 months) and the use of osteoclast-targeted therapy at randomization (yes or no).
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receiving placebo.10,11 The similar incidences of 
seizures, dizziness, and cognitive impairment in 
the darolutamide and placebo groups in the cur-
rent trial may be linked to the low penetration 
of the blood–brain barrier that has been found 
in preclinical studies of the drug.13
These results confirm the benefits of early 
and potent inhibition of androgen-receptor sig-
naling in patients with nonmetastatic, castration-
resistant prostate cancer.25 Other trials, such as 
the LATITUDE and STAMPEDE (Systemic Therapy 
in Advancing or Metastatic Prostate Cancer: Eval-
uation of Drug Efficacy) trials of abiraterone add-
ed to androgen-deprivation therapy in patients 
with castration-sensitive prostate cancer, have sim-
ilarly confirmed that early inhibition of androgen-
receptor signaling offers significant survival ben-
efits to patients.26,27 In addition to survival benefit, 
quality of life is also an important factor in making 
treatment choices for patients with nonmetastat-
ic, castration-resistant prostate cancer,28 since it 
can be negatively affected by adverse events re-
sulting from therapies and medical interventions 
as well as from symptomatic disease progression. 
In the current trial, darolutamide treatment did 
not adversely affect quality of life, and it resulted 
in delayed occurrence of metastases with a favor-
able safety profile.
This trial has several strengths. The large size 
enabled a robust statistical analysis as well as 
the detection of rare but important safety signals. 
Patients’ quality of life was assessed in detail with 
the use of validated instruments to assess differ-
ent aspects of the effect of treatment, including 
the BPI scale to measure pain progression. A limi-
tation of the trial is the underrepresentation of 
patients of African descent (52 in total); there-
fore, no conclusions can be drawn about efficacy 
in this group. In addition, treatment with subse-
quent life-prolonging therapy after the onset of 
metastases in the placebo group could potentially 
affect the observed relative benefits of darolu-
Adverse Event*
Darolutamide 
(N = 954)
Placebo 
(N = 554)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Any adverse event 794 (83.2) 236 (24.7) 426 (76.9) 108 (19.5)
Serious adverse event 237 (24.8) 151 (15.8) 111 (20.0) 70 (12.6)
Grade 5 adverse event 37 (3.9) — 18 (3.2) —
Adverse event leading to discontinua-
tion of the trial regimen
85 (8.9) 32 (3.4) 48 (8.7) 24 (4.3)
Adverse events that occurred in ≥5% of 
patients in either group
Fatigue 115 (12.1) 4 (0.4) 48 (8.7) 5 (0.9)
Back pain 84 (8.8) 4 (0.4) 50 (9.0) 1 (0.2)
Arthralgia 77 (8.1) 3 (0.3) 51 (9.2) 2 (0.4)
Diarrhea 66 (6.9) 0 31 (5.6) 1 (0.2)
Hypertension 63 (6.6) 30 (3.1) 29 (5.2) 12 (2.2)
Constipation 60 (6.3) 0 34 (6.1) 0
Pain in an extremity 55 (5.8) 0 18 (3.2) 1 (0.2)
Anemia 53 (5.6) 8 (0.8) 25 (4.5) 2 (0.4)
Hot flush 50 (5.2) 0 23 (4.2) 0
Nausea 48 (5.0) 2 (0.2) 32 (5.8) 0
Urinary tract infection 47 (4.9) 6 (0.6) 28 (5.1) 3 (0.5)
Urinary retention 33 (3.5) 15 (1.6) 36 (6.5) 11 (2.0)
Table 3. Adverse Events.
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tamide with regard to secondary end points. The 
percentages of patients who received subsequent 
treatment are lower than those reported in the 
SPARTAN trial, in which the trial design included 
the provision of abiraterone for patients in whom 
metastases developed.
In conclusion, metastasis-free survival was sig-
nificantly longer with darolutamide than with 
placebo for men with nonmetastatic, castration-
resistant prostate cancer and a PSA doubling time 
of 10 months or less. The results for the second-
ary and exploratory end points supported the 
Adverse Event*
Darolutamide 
(N = 954)
Placebo 
(N = 554)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Adverse events of interest
Fatigue or asthenic conditions† 151 (15.8) 6 (0.6) 63 (11.4) 6 (1.1)
Bone fracture‡ 40 (4.2) 9 (0.9) 20 (3.6) 5 (0.9)
Falls, including accident§ 40 (4.2) 8 (0.8) 26 (4.7) 4 (0.7)
Seizure, any event 2 (0.2) 0 1 (0.2) 0
Rash¶ 28 (2.9) 1 (0.1) 5 (0.9) 0
Weight decrease, any event 34 (3.6) 0 12 (2.2) 0
Dizziness, including vertigo 43 (4.5) 2 (0.2) 22 (4.0) 1 (0.2)
Cognitive disorder 4 (0.4) 0 1 (0.2) 0
Memory impairment 5 (0.5) 0 7 (1.3) 0
Change in mental status 0 0 1 (0.2) 0
Hypothyroidism 2 (0.2) 0 0 0
Cerebral ischemia‖ 13 (1.4) 7 (0.7) 8 (1.4) 4 (0.7)
Coronary-artery disorder** 31 (3.2) 16 (1.7) 14 (2.5) 2 (0.4)
Heart failure†† 18 (1.9) 5 (0.5) 5 (0.9) 0
*  Exposure-adjusted incidences of adverse events in the darolutamide group and the placebo group were as follows:
 fatigue or asthenic conditions (11.3 patients per 100 years of exposure and 11.1 patients per 100 years of exposure,
respectively), back pain (6.3 and 8.8), arthralgia (5.8 and 9.0), diarrhea (4.9 and 5.5), hypertension (4.7 and 5.1), con-
stipation (4.5 and 6.0), pain in extremity (4.1 and 3.2), anemia (4.0 and 4.4), hot flush (3.7 and 4.1), nausea (3.6 and
5.6), weight loss (2.5 and 2.1), falls (2.7 and 4.1), bone fracture (3.0 and 3.5), memory impairment (0.4 and 1.2), cog-
nitive disorder (0.3 and 0.2), and seizure (0.2 and 0.2).
†  This category combines the following Medical Dictionary for Regulatory Activities, version 20.0 (MedDRA) terms: asthenic 
conditions, disturbances in consciousness, decreased strength and energy, malaise, lethargy, asthenia, and fatigue.
‡  This category combines the following MedDRA terms: any fractures and dislocations, limb fractures and dislocations, 
skull fractures, facial bone fractures and dislocations, spinal fractures and dislocations, and thoracic cage fractures
and dislocations.
§  All events that had been recorded under the MedDRA term “accident” were determined to have been accidental falls
and are included in this category.
¶  This category combines the following MedDRA terms: dermatitis, erythema, rash, macular rash, maculopapular rash, 
papular rash, and pustular rash.
‖  This category combines the following MedDRA terms: cerebral infarction, cerebral ischemia, cerebrovascular accident, 
ischemic stroke, and transient ischemic attack. Grade 5 events occurred in one patient receiving darolutamide and
three patients receiving placebo.
**  This MedDRA High Level Group Term includes coronary-artery disorders not elsewhere classified, coronary-artery 
 arteriosclerosis, coronary artery disease, coronary-artery occlusion, and coronary-artery stenosis. Grade 5 events
 occurred in three patients receiving darolutamide and one patient receiving placebo.
††  This MedDRA High Level Group Term includes heart failure not elsewhere classified, cardiac failure, acute cardiac 
failure, chronic cardiac failure, congestive cardiac failure, and cardiogenic shock. Grade 5 events occurred in four
 patients receiving darolutamide and three patients receiving placebo.
Table 3. (Continued.)
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benefits of darolutamide in this clinical context. 
The safety data indicated no clinically relevant 
difference between darolutamide and placebo in 
the incidence of adverse events that occurred dur-
ing the treatment period, including falls, frac-
tures, seizures, cognitive disorders, and hyperten-
sion. Quality-of-life outcomes were similar in the 
two groups.
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